Antibodies as therapeutic agents: Vive la renaissance!

Expert Opinion on Biological Therapy

Volumn 3, Issue 7, 2003, Pages 1133-1152

  Stockwin, L H ^b   Holmes, S ^a  

^a Domantis Limited   (United Kingdom)

^b Division of Therapeutic Antibodies   (United Kingdom)

Author keywords

Antibody; Cancer; Fab; Infectious disease; Inflammation; Single chain; Single domain; Therapeutic

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; AMG 714; ANTIBODY; BASILIXIMAB; BEC 2; BERTILIMUMAB; BEVACIZUMAB; CANCER VACCINE; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; DOXORUBICIN; EDRECOLOMAB; EFALIZUMAB; EPRATUZUMAB; ETANERCEPT; G 250; GALIXIMAB; GEMTUZUMAB OZOGAMICIN; HU901 DM1; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; IPILIMUMAB; LERDELIMUMAB; LUMILIXIMAB; MDX H210; MEPOLIZUMAB; METELIMUMAB; MLN 02; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PENTUMOMAB; PLANTIBODY; RITUXIMAB; SCH 55700; SEVIRUMAB; SGN 15; SMART ID10; SMART M195; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGINA PECTORIS; ANIMAL MODEL; ASTHMA; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY CANCER; KIDNEY TRANSPLANTATION; LEUKEMIA; LUNG CANCER; MOUSE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; PSORIASIS; RAT; REVIEW; RHEUMATOID ARTHRITIS; STOMACH CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ULCERATIVE COLITIS; VIRUS INFECTION;

ANIMALS; ANTIBODIES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULINS;

ANIMALIA; CYTOMEGALOVIRUS; FELIS CATUS; MURINAE;

EID: 0142087554     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.7.1133     Document Type: Review

References (193)

1. WINAU F, WINAU P- Emil von Behring and serum therapy. Microbes Infect. (2002) 4(2):185-188.
2. KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256(5517):495-497.
3. VAN WAUWE JP, DE MAY JR, GOOSSENS JG: OKT-3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J. Immunol. (1980) 124(6):2708-2713.
4. HALE G, BRIGHT S, CHUMBLEY G et al.: Removal of T cells from bone marrow for transplantation: a monoclonal anti-lymphocyte antibody that fixes human complement. Blood (1983) 62:873-882.
5. MEEKER TC, LOWEDER J, CLEARY ML et al.: A clinical trial of anti-idiotype therapy for B cell malignancy. Blood (1985) 65:1349-1363.
6. COSIMI AB, BURTON RC, COLVIN RB et al.: Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation. (1981) 32(6):535-539.
7. SHAWLER DL, BARTHOLOMEW RM, SMITH LM, DILLMAN RO: Human response to multiple injections of murine monoclonal IgG. J. Immunol. (1985) 135:1530-1535.
8. ECHOLS H: Operators and promoters: the story of molecular biology and its creators. University of California press, CA, USA (2001).
9. MORRISON SL, JOHNSON MJ, HERZENBERG LA, OI VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA (1984) 81(21):6851-6855.
10. BOULIANNE GL, HOZUMIN, SHULMAN MJ: Production of functional chimaeric mouse/human antibody. Nature (1984) 312(5995):643-646.
11. JONES PT, DEAR PH, FOOTE J, NEUBERGER MS, WINTER G: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (1986) 321(6069):522-525.
12. FRANKLIN EC: Structure and function of immunoglobulins. Acta Endocrinol. Suppl. (Copenh.) (1975) 194:77-95.
13. BOES M: Role of natural and immune IgM antibodies in immune responses. Mol. Immunol. (2000) 37:1141-1149.
14. LESLIE GA, MARTIN LN: Structure and function of serum and membrane immunoglobulin D (IgD). Contemp. Top. Mol. Immunol. (1978) 7:1-49.
15. NITSCHKE L, KOSCO MH, KOHLER G, LAMERS MC: Immunoglobulin D-deficient mice can mount normal immune responses o thymus-independent and -dependent antigens. Proc. Natl. Acad. Sci. USA (1993) 90(5):1887-1891.
16. ROES J, RAJEWSKY K: Immunoglobulin D (IgD)-deficient mice reveal an auxiliary receptor function for IgD in antigen-mediated recruitment of B cells. J. Exp. Med. (1993) 177(1):45-55.
17. BAIRD B, SHOPES RJ, OI VT, ERICKSON J, KANE P, HOLOWKA D: Interaction of IgE with its high-affinity receptor. Structural basis and requirements for effective cross-linking. Int. Arch. Allergy Appl. Immunol. (1989) 88(1-2):23-28.
18. GHETIE V, WARD ES: Transcytosis and catabolism of antibody. Immunol. Res. (2002) 25(2):97-113.
19. CLARK M: Antibody engineering IgG effector mechanisms. Chemical Immunol. (1997) 65:88-110.
20. GREENWOOD J, GORMAN SD, ROUTLEDGE EG, LLOYD IS, WALDMANN H: Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis. Ther. Immunol. (1994) 1(5):247-255.
21. KORTT AA, DOLEZAL O, POWER BE, HUDSON PJ: Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng. (2001) 18(3):95-108.
22. BOUCHER Y, KIRKWOOD JM, OPACIC D, DESANTIS M, JAIN RK: Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. (1991) 51(24):6691-6694.
23. YOKOTA T, MILENIC DE, WHITLOW M, SCHLOM J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. (1992) 52(12):3402-3408.
24. HOLT LJ, HERRING C, JESPERS LS, WOOLVEN BP, TOMLINSON IM: Domain antibodies: proteins for therapy. Trends in Biotechnol (2003) (In Press).
25. CHOY EH, HAZLEMAN B, SMITH M et al.: Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a Phase II double-blinded, randomized, dose-escalating trial. Rheumatol. (Oxf) (2002) 41(10):1133-1137.
26. GUSSOW D, WARD ES, GRIFFITHS AD, JONES PT, WINTER G: Generating binding activities from E. coli by expression of a repertoire of immunoglobulin variable domains. Cold Spring Harb. Symp. Quant. Biol. (1989) 54(Pt 1):265-272.
27. MARKS JD, HOOGENBOOM HR, BONNERT TP, MCCAFFERTY J, GRIFFITHS AD, WINTER G: By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol Biol. (1991) 221:581-597.
28. GRIFFITHS AD, WILLIAMS SC, HARTLEY O et al.: Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. (1994) 13:3245-3260.
29. VAUGHAN TP, AJ WILLIAMS, PRITCHARD K et al.: Human antibody with sub nanomolar affinity isolated from a large non-immunized phage display library. Nat. Biotechnol. (1996) 14:309-314.
30. FOOTE J, EISEN HN: Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA (1995) 92:1254-1256.
31. KEEFE AD, SZOSTAK JW: Funcional proteins from a random sequence library. Nature (2001) 410:15-18.
32. HANES J, SCHAFFITZEL C, KNAPPIK A, PLUCKTHUN A: Picomolar affinity antibodies from a fully synthetic naïve library selected and evolved by ribosome display. Nat. Biotechnol. (2000) 18:1287-1292.
33. HOOGENBOOM HR: Designing and optimising library selection strategies for generating high affinity antibodies. Trends Biotechnol. (1997) 15:62-70.
34. MCCAFFERTY J, GRIFFITHS AD, WINTER G, CHISWELL DJ: Phage antibodies: filamentous phage displaying antibody variable domains. Nature (1990) 348:552-554.
35. HOOGENBOOM HR, GRIFFITHS AD, JOHNSON KS, CHISWELL DJ, HUDSON P, WINTER G: Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. (1991) 19:4133-4137.
36. KNAPPIK A, GE L, HONEGGER A et al.: Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol (2000) 296(1):57-86.
37. HANES J, PLUCKTHUN A: In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. USA (1997) 94(10):4937-4942.
38. HE M, TAUSSIG MJ: Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res. (1997) 24:5132-5134.
39. BODER ET, WITTRUP KD: Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. (1997) 15(6):553-557.
40. FELDHAUS MJ, SIEGEL RW, OPRESKO LK et al.: Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat. Biotechnol. (2003) 21(2):163-170.
41. ISHIDA I, TOMIZUKA K, YOSHIDA H et al.: Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells (2002) 4(1):91-102.
42. JAKOBOVITS A, MOORE A, GREEN L et al.: Germ-line transmission and expression of a human-derived yeast artificial chromosome. Nature (1993) 362(6417):255-258.
43. GREEN L,HARDY M, MAYNARD-CURRY K et al.: Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. (1994) 7(1):13-21.
44. K monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. (1996) 14:845-851.
45. BARRY MA, BARRY ME, JOHNSTON SA. Production of monoclonal antibodies by genetic immunization. Biotechniques (1994) 16:616-618.
46. DONNELLY JJ, ULMER JB, LIU MA: Immunization with DNA. J. Immunol. Methods (1994) 176(2):145-152.
47. PEREIRA S, VAN BELLE P, ELDER D et al.: Combinatorial antibodies against human malignant melanoma-Hybridoma (1997) 16(1):11-16.
48. SZARDENINGS M, TOMROTH S, MUTILIS F et al.: Phage display selection on whole cells yields a peptide specific for melanocortin receptor 1. J. Biol. Chem. (1997) 272(44):27943-27948.
49. MORAN E, O'KEEFE M, O'CONNER R, LARIGN AM, MURPHY P, CLYNES M: Methods for generation of monoclonal antibodies to the very small drug hapten, 5-benzimidazolecarboxylic acid. J. Immunol. Methods (2002) 271(1-2):65-75.
50. RAHBARIZADEH F, RASAEE MJ, MANDANI R, RAHBARIZADEH MH, OMIDFAR K: Preparation and characterisation of specific and high-affinity monoclonal antibodies against morphine. Hybridoma (2000) 19(5):413-417.
51. GAO C, MAO S, RONCA F et al.: Denovo identification of tumor-specific internalizing human antibody-receptor pairs by phage-display methods. J. Immunol. Methods (2003) 274(1-2):185-197.
52. HOOGENBOOM HR, CHAMES P: Natural and designer binding sites made by phage display technology. Immunol. Today (2000) 21:371-378.
53. SAVOCA R, SCHWAB C, BOSSARD HR: Epitope mapping employing immobilised synthetic peptides. How specific is the reactivity of these peptides with antisera raised against the parent protein? J. Immunol. Methods (1991) 141(2):245-252.
54. NERI D, MONTIGIANI S, KIRKHAM PM: Biophysical methods for the determination of antibody-antigen affinities. Trends Biotechnol. (1996) 14(12):465-470.
55. SWANSON SJ: New technologies for the detection of antibodies to therapeutic proteins. Dev. Biol. (2003) 112:127-133.
56. NAGY ZA, HUBNER B, LOHNING C et al.: Fully human HLA-DR-specific monoclonal antibodies efficiently induce programmed cell death of malignant lymphoid cells. Nat. Med. (2002) 8(8):801-807.
57. ROEHRIG JT, HUNT AR, KINNEY RM, MATHEWS JH: In vitro mechanisms of monoclonal antibody neutralisation of alphavirus. Virology (1988) 165(1):66-73.
58. ADAMS GP, SCHIER R, MCCALL AM et al.: High affinity restricts the localisation and tumor penetration of single chain Fv antibody molecules. Cancer Res. (2001) 61:4750-4755.
59. GARBER K: Biotech industry faces new bottleneck. Nat. Biotechnol. (2001) 19(3):184-185.
60. HUMPHREYS DP, GLOVER DJ: Therapeutic antibody production technologies: molecules, applications, expression and purification. Curr. Opin. Drug. Discov. Dev. (2001) 4(2):172-185.
61. MORRISON SL: In vitro antibodies: strategies for production and application. Ann. Rev. Immunol. (1992) 10:239-265.
62. SIMMONS LC, REILLY D, KLIMOWSKI L et al: Expression of full-length immunoglobins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J. Immunol. Methods (2002) 263(1-2):133-147.
63. MUKHTAR M, PARVEEN Z, POMERANTZ RJ: Technology evaluation: PRO-542, Progenics Pharmaceuticals, Inc. Curr. Opin. Mol. Ther. (2000) 2(6):697-702.
64. YEUNG PK: Technology evaluation: transgenic antithrombin HI (rhAT-III), Genzyme Transgenics. Curr. Opin. Mol. Ther. (2000) 2(3):336-339.
65. WRIGHT G, CARVER A, COTTOM D et al.: High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep. Biotechnology (NY) (1991) 9(9):830-834.
66. FISCHER R, TWYMAN RM, SCHILLBERG S: Production of antibodies in plants and their use for global health. Vaccine (2003) 21(7-8):820-825.
67. ISHII Y, TAKAMI T, YUASA H, TAKEI T, KIKUCHI K: Two distinct antigen systems in human B lymphocytes: identification of cell surface and intracellular antigens using monoclonal antibodies. Clin. Exp. Immunol. (1984) 58(1):183-192.
68. JOHNSON P, GLENNIE M: The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol. (2003) 30:3-8.
69. MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al.: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 90(6):2188-2195.
70. COIFFIER B, HAIOUN C, KETTERER N et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood (1998) 92(6):1927-1932.
71. HAINSWORTH JD, LITCY S, BARTON JH et al.: Minnie Pearl Cancer Research Network. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer. J. Clin. Oncol. (2003) 21(9):1746-1751.
72. HESS G, FLOHR T, HUBER C, KOLBE K, DERIGS HG, FISCHER T: Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma. Bone Marrow Transplant. (2003) 31(9):775-782.
73. WITZIG TE, GORDON LI, CABANILLAS F et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. (2002) 20(10):2453-2463.
74. GARBER K: ODAC panel gives nod to Bexxar. J. Natl. Cancer Inst. (2003) 95(3):189.
75. ZEIN N, SINHA AM, MCGAHREN WJ, ELLESTAD GA: Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science (1988) 240(4856):1198-1201.
76. SIEVERS EL, LARSON RA, STADTMAUER EA et al.: Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. (2001) 19(13):3244-3254.
77. ROSENBLUM MG, HORN SA, CHEUNG LH: A novel recombinant fusion toxin targeting HER2-NEU-over-expressing cells and containing human tumor necrosis factor. Int. J. Cancer (2000) 88(2):267-273.
78. RYBAK SM, NEWON DL: Natural and engineered cytotoxic ribonucleases: therapeutic potential. Exp. Cell. Res. (1999) 253(2):325-335.
79. NEWTON DL, HANSEN HJ, MIKULSKI SM, GOLDENBERG DM, RYBAK SM: Potent and specific antitumour effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkins lymphoma. Blood (2001) 97:528-535.
80. DYER MJ: The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin. Oncol. (1999) 26(5, Suppl. 14):52-57.
81. HALE G, BRIGHT S, CHUMBLEY G et al.: Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood (1983) 62:873-882.
82. XIA MQ, TONE M, PACKMAN L, HALE G, WALDMANN H: Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and CDNA cloning reveal an unusually small peptide backbone. Eur. J. Immunol. (1991) 21:1677.
83. BRETT SJ, BAXTER G, COOPER H et al.: Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment. Int. Immunol. (1996) 8(3):325-334.
84. RIECHMANN L, CLARK MR, WALDMANN H, WINTER G: Reshaping human antibodiess for therapy. Nature (1998) 332:323-327.
85. HALE G, DYER MJS, CLARK MR et al.: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet (1988) 2:1394-1399.
86. KEATING MJ, FLINN I, JAIN V et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood (2002) 15(10):3554-3561.
87. LEONARD JP, LINK BY: Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and HulD10 (apolizumab). Semin. Oncol (2002) 29(1, Suppl. 2):81-86.
88. SCHOPF RE: IDEC-114 (IDEC). Curr. Opin. Investig. Drugs (2001) 2(5):635-638.
89. DING C, JONES G: Technology evaluation: MRA, Chugai. Curr. Opin. Mol. Ther. (2003) 5(1):64-69.
90. OZAKI S, KOSAKA M, WAKATSUKI S, ABE M, KOISHIHARA Y, MATSUMOTO T: Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood (1997) 90(8):3179-3186.
91. DI FIORE PP: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (1987) 237:178-182.
92. HOLBRO T, CIVENNI G, HYNES NE: The ErbB receptors and their role in cancer progression. Exp. Cell Res. (2003) 284(1):99-110.
93. SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244(4995):707-712.
94. SLIWKOWSKI MX, LOFGREN JA, LEWIS GD, HOTALING TE, FENDLY BM, FOX JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. (1999) 26(4 Suppl. 12):60-70.
95. CLYNES RA, TOWERS TL, PRESTA LG, RAVETCH JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. (2000) 6(4):443-446.
96. DREBIN JA, LINK VC, STERN DF, WEINBERG RA, GREENE MI: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell (1985) 41:697-706.
97. EIERMANN W: International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann. Oncol. (2001) 12:S57-S62.
98. VOGEL C, COBLEIGH MA, TRIPATHY D et al.: First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report. Eur. J. Cancer. (2001) 37(1):25-29.
99. AGUS DB, AKITA RW, FOX WD et al.: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 2(2):127-137.
100. MOLINA MA, CODONY-SERVAT J, ALBANELL J, ROJO F, ARRIBAS J, BASELGA J: Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. (2001) 61(12):4744-4749.
101. RITTER CA, ARTEAGA CL: The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol. (2003) 30(1 Suppl. 1):3-11.
102. GILL GN, KAWAMOTO T, COCHET C et al.: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. (1984) 259(12):7755-7760.
103. WINKLER ME, O'CONNOR L, WINGET M, FENDLY B: Epidermal growth factor and transforming growth factor alpha bind differently to the epidermal growth factor receptor. Biochemistry (1989) 28(15):6373-6378.
104. YANG XD, JIA XC, CORVALAN JR, WANG P, DAVIS CG, JAKOBOVITS A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. (1999) 59(6):1236-1243.
105. OVERHOLSER JP, PREWETT MC, HOOPER AT, WAKSAL HW, HICKLIN DJ: Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer (2000) 89(1):74-82.
106. SCHWARTZ G, DUTCHER J, VOGELZANG N et al.: Phase II clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). American Society of Clinical Oncology, Annual Meeting, Florida, USA (2002).
107. HIRD V, MARAVEYAS A, SNOOK D et al.: Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer (1993) 68(2):403-406.
108. POSEY JA, KHAZAELI MB, DELGROSSO A et al.: A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother. Radiopharm (2001) 16(2):125-132.
109. SMITH S: Technology evaluation: SGN-15, Seattle Genetics, Inc. Curr. Opin. Mol. Ther. (2001) 3(3):295-302.
110. KENNETT RH: Technology evaluation; WX-G250, Wilex/Ludwig Institute for Cancer Research. Curr. Opin. Mol. Ther. (2003) 5(1):70-75.
111. FERNANDO NH, HURWITZ HI: Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin. Oncol. (2003) 30(3 Suppl. 6):39-50.
112. KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21(1):60-65.
113. MIN HY, DOYLE LV, VITT CR et al.: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. (1996) 56(10):2428-2433.
114. MURRAY GI, DUNCAN ME, O'NEIL P, MELVIN WT, FOTHERGILL JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. (1996) 2(4):461-462.
115. BRUNET JF, DENIZOT F, LUCIANI MF et al.: A new member of the immunoglobulin superfamily-CTLA-4. Nature (1987) 328:267.
116. LINSLEY PS, BRADY W, URNES M, GROSMAIRE LS, DAMLE NK, LEDBETTER JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. (1991) 174:561.
117. HODI FS, MIHM MC, SOIFFER RJ et al.: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA (2003) 100(8):4712-4717.
118. SHANAHAN JC, ST CLAIR W: Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. Clin. Immunol. (2002)103(3 Pt 1):231-242.
119. SAKLATVALA J: Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature (1986) 322(6079):547-549.
120. HUSBY G, WILLIAMS RC JR. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J. Autoimmun. (1988) 1(4):363-371.
121. WILLIAMS RO, FELDMANN M, MAINI RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA (1992) 89(20):9784-9788.
122. LORENZ HM: Technology evaluation: adalimumab, Abbott laboratories. Curr. Opin. Mol. Ther. (2002)4(2):185-190.
123. KEATING GM, PERRY CM: Inflixab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Bio Drugs (2002) 16(2):111-148.
124. HARRIMAN G, HARPER LK, SCHAIBLE TF: Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNEalpha treatment. Ann. Rheum. Dis. (1999) 58(Suppl. 1):161-164.
125. RAU R: Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann. Rheum. Dis. (2002) 61(Suppl. 2):ii70-ii73.
126. BRANDT J, KHARIOUZOV A, LISTING J et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. (2003) 48(6):1667-1675.
127. MIZEL SB, DAYER JM, KRANE SM, MERGENRAGEN SE: Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). Proc. Natl. Acad. Sci. USA (1981) 78(4):2474-2477.
128. LAST-BARNEY K, HOMON CA, FAANES RB, MERLUZZI NJ: Synergistic and overlapping activities of tumor necrosis factor-alpha and IL-1. J. Immunol. (1988) 141(2):527-530.
129. KARY S,BURMESTER GR: Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int. J. Clin. Pract. (2003) 57(3):231-234.
130. CHAN SH, PERUSSIA B, GUFTA JW et al.: Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. Exp. Med. (1991) 173(4):869-879.
131. BUTLER DM, MALFAIT AM, MAINI RN, BRENNAN FM, FELDMANN M: Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur. J. Immunol. (1999) 29(7):2205-2212.
132. GRABSTEIN KH, EISENNIAN J, SHANEBECK K et al.: Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science (1994) 264(5161):965-968.
133. LODOLCE J, BURKETT P, KOKA R et al.: Interleukin-15 and the regulation of lymphoid homeostasis. Mol. Immunol. (2002) 9:537-544.
134. MCINNES IB, AL-MUGHALES J, FIELD M et al.: The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. (1996) 2(2):175-182.
135. LINTON SM, MORGAN BP: Complement activation and inhibition in experimental models of arthritis. Mol. Immunol. (1999) 36(13-14):905-914.
136. KAPLAN M: Eculizumab (Alexion). Curr. Opin. Investig. Drugs (2002) 3(7):1017-1023.
137. MOK CC, LAU CS: Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. (2003) 56(7):481-490.
138. CHEEMA GS, ROSCHKE V, HILBERT DM, STOHL W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. (2001) 44(6):1313-1319.
139. MARIETTE X, ROUX S, ZHANG J et al.: The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann. Rheum. Dis. (2003) 62(2):168-171.
140. KNIGGE KL: Inflammatory bowel disease. Clin Cornerstone (2002) 4(4):49-60.
141. MEENAN J, SPAANS J, GROOL TA, PALS ST, TYTGAT GN, VAN DEVENTER SJ: Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation. Gut (1997) 40(2):241-246.
142. GHOSH S, GOLDIN E, GORDON FH et al.: Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. N. Engl. J. Med. (2003) 348(1):24-32.
143. REDDY MP, KINNEY CA, CHAIKIN MA et al.: Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J. Immunol. (2000) 164(4):1925-1933.
144. BAYES M, RABASSEDA X, PROUS JR: Gateways to clinical trials. Methods Final. Exp. Clin. Pharmacol. (2002) 24(6):371-391.
145. SILVERMAN GJ, WEISMAN S: Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. (2003) 48 (6): 1484-1492.
146. SAINI SS, MACGLASHAN D: How IgE upregulates the allergic response. Curr. Opin. Immunol. (2002) 14(6):694-697.
147. FINN A, GROSS G, VAN BAVEL J et al.: Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J. Allergy Clin. Immunol. (2003) 111(2):278-284.
148. BUHL R, HANF G, SOLER M et al.: The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur. Respir. J. (2002) 20(5):1088-1094.
149. PRUSSIN C, METCALFE DD: IgE, mast cells, basophils, and eosinophils. J. Allergy Clin. Immunol. (2003) 111(2, Suppl.):S486-S494.
150. ROMAGNANI S: Cytokines and chemoartractants in allergic inflammation. Mol. Immunol. (2002) 38(12-13):881-885.
151. HART TK, COOK RM, ZIA P et al.: Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J. Allergy Clin. Immunol. (2001) 108:250-257.
152. RUSSELL AD: Antibiotic and biocide resistance in bacteria: introduction. J. Appl. Microbiol. (2002) 92(Suppl.):1S-3S.
153. ROMERO JR: Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr. Infect. Dis. J. (2003) 22(2 Suppl.):S46-S54.
154. JOHNSON S, OLIVER C, PRINCE GA et al.: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. (1997) 176(5):1215-1224.
155. NO AUTHORS LISTED: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics (1998) 102(3 Pt 1):531-537.
156. GILPIN AM, HOLBROOK JT, JABS DA, MEINERT CL: Studies of ocular complications of AIDS Research Group. Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial. Control Clin. Trials (2003) 24(1):92-98.
157. WITHERELL G: XTL-001.XTL Pharmaceuticals. Curr. Opin. Investig. Drugs (2002) 3(5):684-692.
158. BOON L, HOLLAND B, GORDON W et al.: Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: pre-clinical assessment in non-human primates. Toxicology (2002) 172(3):191-203.
159. ARMBRUSTER C, STEIGLER GM, VCELAR BA et al.: A Phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS (2002) 16(2):227-233.
160. GALUN E, EREN R, SAFADI R et al.: Clinical evaluation (Phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties. Hepatology (2002) 35(3):673-679.
161. VOSSEN MT, WESTERHOUT EM, SODERBERG-NAUCLER C, WIERTZ EJ: Viral immune evasion: a masterpiece of evolution. Immunogenetics (2002) 54(8):527-542.
162. ZAMBRANO-VILLA S, ROSALES-BORJAS D, CARRERO JC, ORTIZ-ORTIZ L: How protozoan parasites evade the immune response. Trends Parasitol. (2002) 18(6):272-278.
163. HALTER R, POHLNER J, MEYER TF: Mosaic-like organization of IgA protease genes in Neisseria gonorrhoeae generated by horizontal genetic exchange in vivo. EMBO J. (1989) 8(9):2737-2744.
164. JOOSTEN SA, VAN KOOTEN C, PAUL LC: Pathogenesis of chronic allograft rejection. Transpl. Int. (2003) 16(3):137-145.
165. NO AUTHORS LISTED: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N. Engl. J. Med. (1985) 313(6):337-342.
166. UCHIYAMA T, BRODER S, WALDMANN TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J. Immunol. (1981) 126:1393.
167. SHAH M, FOREMAN DM, FERGUSON MW: Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet (1992) 339(8787):213-214.
168. IHN H, YAMANE K, KUBO M, TAMAKI K: Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum. (2001) 44(2):474-480.
169. SIRIWARDENA D, KHAW PT, KING AJ et al.: Human antitransforming growth factor beta(2) monoclonal antibody-a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology (2002) 109(3):427-431.
170. KHAW PT, WELLS AP, GREEN C et al.: Three year follow-up of an early phase clinical trial of CAT-152 anti-TGFβ2 human monoclonal antibody as an adjunct to first time trabeculectomy. Invest. Ophthalmol. Vis. Sci. (2003) 44:1198.
171. BABB JD: Thrombolysis and intervention in acute myocardial infarction: an overview. J. Atheroscler. Thromb. (1995) 2(1):1-13.
172. VIVEKANANTHAN DP, PATEL VB, MOLITERNO DJ: Glycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute myocardial infarction. J Interv. Cardiol. (2002) 15(2):131-139.
173. IBBOTSON T, MCGAVIN JK, GOA KL: Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs (2003) 63(11):1121-1163.
174. TCHENG JE: Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am. J. Cardiol. (1996) 78(3A):35-40.
175. MOCCO J, CHOUDHRI T, HUANG J et al.: HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ. Res. (2002) 91(10):907-914.
176. JAMES ND, ATHERTON PJ, JONES J et al.: A Phase II study of the bispecific antibody MDX-H2 10 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer. Br. J. Cancer (2001) 85:152-156.
177. BORCHMANN P, SCHNELL R, FUSS I et al.: Phase I trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood (2002) 100(9):3101-3107.
178. LOFFLERA, GRUEN M, WUCHTER C et al.: efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia (2003) 17(5):900-909.
179. GRANT SC, KRIS MG, HOUGHTON AN, CHAPMAN PB: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin. Canter Res. (1999) 5(6):1319-1323.
180. LUNDE E, WESTERN KH, RASMUSSEN IB, SANDLIE I, BOGEN B: Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies. J. Immunol. (2002) 168(5):2154-2162.
181. PARK YS: Tumor-directed targeting of liposomes. Biosci Rep. (2002) 22(2):267-281.
182. LOPEZ DE MENEZES DE, PILARSKI LM, ALLEN TM: In vitro and in vivo targeting of immunoliposomial doxorubicin to human B-cell lymphoma. Cancer Res. (1998) 58:3320-3330.
183. KIRPOTIN DB, PARK K, HONG S et al.: Sterically stabilised anti-Her2
184. PEPEBOEV AV, ASIEDU CK, KAWAKAMI Y et al.: Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Ther. (2002) 9:1189-1193.
185. PARNEY IF, CHANG LJ: Cancer immunogene therapy: a review. J. Biomed Sci. (2003) 10:37-43.
186. NATHAN C: Catalytic antibody bridges innate and adaptive immunity. Science (2002) 298(5601):2143-2144.
187. DENG SX, DE PRADA P, LANDRY DW: Anticocaine catalytic antibodies. J. Immunol. Methods (2002) 269(1-2):299-310.
188. COHEN PA: Intrabodies. Targeting scFv expression to eukaryotic intracellular compartments. Methods Mol. Biol. (2002) 178:367-378.
189. TANAKA T, RABBITTS TH: Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. EMBO J. (2003) 22(5):1025-1035.
190. SHIELDS RL, NAMENUK AK, HONG K et al.: High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. (2001) 276(9):6591-6604.
191. JACOBS TW, GOWN AM, YAZIJI H, BARNES MJ, SCHNITT SJ: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol. (1999) 17(7):1983-1987.
192. http://wwwgene.com Genentech products and clinical trials page.
193. http://www.IDECpharm.com IDEC Pharmaceuticals website.